Exclusive Summary

• Dobutamine Hydrochloride Injection is a WHO essential medicine and clinically indispensable product, with a stable and large global market demand for severe heart failure and cardiogenic shock.
• The originator's patent has long expired, creating a mature global generic market ripe for new entrants, and your product's bioequivalence approval and API self-sufficiency provide a competitive edge.
• As a short-acting inotropic agent, it is widely recommended in guidelines for short-term supportive treatment, possessing clear and irreplaceable clinical value.
• Its designation as a Category A drug in China's medical insurance and a nationally recognized clinically essential and short-supply medicine offers strong support for market access and reimbursement in various countries and regions.
• Your Chinese product demonstrates advantages in quality, cost, and compliance, especially appealing amidst current global demands for supply chain diversification.

Asset Materials

Contact Us for Full Materials